These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 18519690)

  • 41. Utility of Immunohistochemistry With Antibodies to SS18-SSX Chimeric Proteins and C-Terminus of SSX Protein for Synovial Sarcoma Differential Diagnosis.
    Lasota J; Chłopek M; Kaczorowski M; Natálie K; Ryś J; Kopczyński J; Sulaieva O; Michal M; Kruczak A; Harazin-Lechowska A; Szczepaniak M; Koshyk O; Hałoń A; Czapiewski P; Abdullaev Z; Kowalik A; Aldape KD; Michal M; Miettinen M
    Am J Surg Pathol; 2024 Jan; 48(1):97-105. PubMed ID: 37899499
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
    Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JS; Kuntz KK; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H
    PLoS One; 2016; 11(7):e0158888. PubMed ID: 27391784
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel SYT-SSX fusion transcript variants in synovial sarcoma.
    Dimitriadis E; Rontogianni D; Kyriazoglou A; Takou A; Frangia K; Pandis N; Trangas T
    Cancer Genet Cytogenet; 2009 Nov; 195(1):54-8. PubMed ID: 19837269
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein.
    Yoneda Y; Ito S; Kunisada T; Morimoto Y; Kanzaki H; Yoshida A; Shimizu K; Ozaki T; Ouchida M
    PLoS One; 2013; 8(10):e77564. PubMed ID: 24130893
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Frequent TRPS1 expression in synovial sarcoma is associated with SS18-SSX fusion oncoprotein activity.
    Cloutier JM; Ingram DR; Wani K; Lazar AJ; Wang WL
    Hum Pathol; 2022 Dec; 130():88-94. PubMed ID: 36162599
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma.
    Wakamatsu T; Naka N; Sasagawa S; Tanaka T; Takenaka S; Araki N; Ueda T; Nishizawa Y; Yoshikawa H; Itoh K
    Cancer Sci; 2014 Sep; 105(9):1124-34. PubMed ID: 24975049
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Release of circulating tumor cells and cell-free nucleic acids is an infrequent event in synovial sarcoma: liquid biopsy analysis of 15 patients diagnosed with synovial sarcoma.
    Mihály D; Nagy N; Papp G; Pápai Z; Sápi Z
    Diagn Pathol; 2018 Oct; 13(1):81. PubMed ID: 30326929
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interdependence of SS18-SSX-driven YAP1 and β-Catenin Activation in Synovial Sarcoma.
    Isfort I; Berthold R; Heinst L; Wardelmann E; Larsson O; Trautmann M; Hartmann W
    Mol Cancer Res; 2023 Jun; 21(6):535-547. PubMed ID: 36920288
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic value of SS18-SSX fusion type in synovial sarcoma; systematic review and meta-analysis.
    Kubo T; Shimose S; Fujimori J; Furuta T; Ochi M
    Springerplus; 2015; 4():375. PubMed ID: 26217552
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the polycomb complex protein Bmi1.
    Barco R; Garcia CB; Eid JE
    PLoS One; 2009; 4(4):e5060. PubMed ID: 19337376
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Disruption of HDAC4/N-CoR complex by histone deacetylase inhibitors leads to inhibition of IL-2 gene expression.
    Matsuoka H; Fujimura T; Hayashi M; Matsuda K; Ishii Y; Aramori I; Mutoh S
    Biochem Pharmacol; 2007 Aug; 74(3):465-76. PubMed ID: 17559812
    [TBL] [Abstract][Full Text] [Related]  

  • 52. First cloned human immortalized adipose derived mesenchymal stem-cell line with chimeric SS18-SSX1 gene (SS-iASC).
    Mihály D; Matula Z; Changchien YC; Papp G; Tátrai P; Sápi Z
    Cancer Genet; 2017 Oct; 216-217():52-60. PubMed ID: 29025595
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recurrent and novel SS18-SSX fusion transcripts in synovial sarcoma: description of three new cases.
    Przybyl J; Sciot R; Rutkowski P; Siedlecki JA; Vanspauwen V; Samson I; Debiec-Rychter M
    Tumour Biol; 2012 Dec; 33(6):2245-53. PubMed ID: 22976541
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma.
    Baranov E; McBride MJ; Bellizzi AM; Ligon AH; Fletcher CDM; Kadoch C; Hornick JL
    Am J Surg Pathol; 2020 Jul; 44(7):922-933. PubMed ID: 32141887
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma.
    Cironi L; Petricevic T; Fernandes Vieira V; Provero P; Fusco C; Cornaz S; Fregni G; Letovanec I; Aguet M; Stamenkovic I
    Sci Rep; 2016 Feb; 6():22113. PubMed ID: 26905812
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genome-wide recruitment to Polycomb-modified chromatin and activity regulation of the synovial sarcoma oncogene SYT-SSX2.
    Garcia CB; Shaffer CM; Eid JE
    BMC Genomics; 2012 May; 13():189. PubMed ID: 22594313
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic implication of SYT-SSX fusion type in synovial sarcoma: a multi-institutional retrospective analysis in Japan.
    Takenaka S; Ueda T; Naka N; Araki N; Hashimoto N; Myoui A; Ozaki T; Nakayama T; Toguchida J; Tanaka K; Iwamoto Y; Matsumine A; Uchida A; Ieguchi M; Kaya M; Wada T; Baba I; Kudawara I; Aoki Y; Yoshikawa H
    Oncol Rep; 2008 Feb; 19(2):467-76. PubMed ID: 18202796
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting epigenetic misregulation in synovial sarcoma.
    Waterfall JJ; Meltzer PS
    Cancer Cell; 2012 Mar; 21(3):323-4. PubMed ID: 22439927
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeted disruption of the synovial sarcoma-associated SS18 gene causes early embryonic lethality and affects PPARBP expression.
    de Bruijn DR; Peters WJ; Chuva de Sousa Lopes SM; van Dijk AH; Willemse MP; Pfundt R; de Boer P; Geurts van Kessel A
    Hum Mol Genet; 2006 Oct; 15(19):2936-44. PubMed ID: 16926188
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Are there geographical differences in the frequency of SYT-SSX1 and SYT-SSX2 chimeric transcripts in synovial sarcoma?
    Koković I; Bracko M; Golouh R; Ligtenberg M; van Krieken HJ; Hudler P; Komel R
    Cancer Detect Prev; 2004; 28(4):294-301. PubMed ID: 15350633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.